1.53 +0.14 (10.07%)
After hours: 7:14PM EDT
|Bid||1.70 x 1300|
|Ask||1.89 x 800|
|Day's Range||1.22 - 1.45|
|52 Week Range||1.10 - 3.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
Applied DNA Sciences Inc. (APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively. Under the terms of the Agreement, LineaRx and Takis/Evvivax will jointly develop linear DNA expression vectors for two of Takis/Evvivax’s anti-cancer vaccine candidates utilizing LineaRx’s linear DNA technology.
Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”) in the field of biotherapeutics, specifically gene and cellular therapies as well as vaccines. The Company believes that the opportunity and markets for these biotherapeutics are substantial, and that its proprietary PCR technology offers the potential for improved outcomes relative to current plasmid and viral vector production technologies.
Applied DNA Sciences Inc., (NASDAQ:APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, announced today the signing of a new contract to continue uninterrupted service of the Company’s DNA marking program at the Defense Logistics Agency’s (DLA) Land and Maritime’s Product Test Center (PTC) in Columbus, Ohio. The contract outlines the Company’s provision of supplies and services, including creation of unique DNA marks in various inks, QC authentication testing and training. “We appreciate the DLA’s continuing support of our taggant technology platform in extending this contract for the marking of system-critical microcircuits,” stated Janice Meraglia, Vice President of Government and Military Programs at Applied DNA.
Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, today announced the closing in the amount of $1.65 million of secured convertible notes (the “Notes”) by way of a non-brokered private placement with accredited investors and certain members of its management team and Board of Directors, led by its Chairman, President and Chief Executive Officer. The Company expects to use the proceeds for general corporate purposes. Having demonstrated success in penetrating large and developing markets with substantial issues with supply chain security, such as the U.S. cotton supply chain, our growing penetration of non-commodity markets offer a path to revenue growth,” said Dr. James A. Hayward, chairman, president and chief executive officer of Applied DNA.
High-Expression Amplicons Facilitate Non-Recombinant Gene Therapies. Hold the Potential to Serve as an Alternative to Plasmids and Viral Vectors. Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, will present a poster entitled “Linear DNA High-Expression Amplicons (HEAs) for Gene Therapy” at the 6th Annual Immuno-Oncology Summit in Boston at the Seaport World Trade Center, August 28-30, 2018.
The Stony Brook, New York-based company said it had a loss of 10 cents per share. The DNA-based security technology company posted revenue of $1 million in the period. In the final minutes of trading on ...
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / Applied DNA Sciences, Inc. (NASDAQ: APDN ) will be discussing their earnings results in their Q3 Earnings Call to be held on August 13, 2018 at 4:30 PM Eastern ...
Applied DNA Sciences, Inc. , announced today it plans to release financial results for its fiscal 2018 third quarter ended June 30, 2018 after market close on Monday, August 13, 2018.
Applied DNA Sciences Inc., (“the Company”) (APDN), among the world’s largest producers of linear DNA, has reached new technical milestones in the growth of its Contract Research (CRO) and Contract Manufacturing (CMO) businesses. In the past 12 months, Applied DNA has shipped over 8,000 milligrams of PCR-produced linear DNA for use in Diagnostic and Therapeutic applications. The Company has completed, or is progressing through, key milestones of a growing number of therapeutics research contracts for companies producing DNA and RNA vaccines and adoptive cell therapies.
PANAMA PACIFICO, Panama, Aug. 1, 2018 /PRNewswire/ -- TheraCann International Benchmark Corporation ("TheraCann"), a leading full service international cannabis business and "seed to sale" technology firm in conjunction with Applied DNA Sciences, Inc., (APDN), the leader in molecular technologies for supply chain transparency, announced the launch of their breakthrough ETCH biotrace™ technology. The molecular "tag and trace" system will be included with TheraCann's BenchmarkSOLUTION of licensing, project management, security, cultivation, and analysis services. TheraCann's ETCH biotrace™ platform is poised to further refine and transform the cannabis regulatory environment by adding capabilities that allow for the forensic tracking of cannabis and cannabis derivatives across the supply chain.
Applied DNA Sciences, Inc., (APDN) (“Applied DNA” or the “Company,”) and Everledger, Inc. (“Everledger”), an independent emerging technology enterprise, have signed a Memorandum of Understanding (“MOU”) to execute a co-marketing and development plan for the two companies’ platforms with an objective of providing integrated physical and digital security for supply chain traceability and certification for high-end brands and products.
“This survey confirms that selling inauthentic products can be extremely detrimental to companies and their brands,” said James A. Hayward, Ph.D., chairman, president and CEO of Applied DNA Sciences.
Applied DNA Sciences, Inc., (APDN), the leader in DNA-based authentication, in conjunction with TheraCann International (TheraCann) will launch the cannabis industry’s first cannabis tagging system (CTS) using Applied DNA’s CertainT® platform of tag, test and track. The device is designed to rapidly molecularly tag cannabis plants in commercial harvests of any scale. Once the molecular tag is applied, the plants and their derivative products can be forensically tracked through every stage of the supply chain all the way to the consumer.
Applied DNA Sciences, Inc. (APDN) (“Applied DNA” or the ”Company“), today announced that it received and shipped a $1.15 million order in its fiscal 2018 third quarter ended June 30, 2018 to tag cotton in the upcoming 2018/2019 ginning season. The order for the Company’s SigNature T® platform technology will be used to tag, test and track three US cotton varietals, Pima, Acala and Delta. “We are pleased that ongoing efforts to build the market for tagged, traceable and sustainable cotton are converting into new orders across all three main US varietals, reflecting recurring use of tagged cotton across the home textile category,” said Dr. James A. Hayward, president and CEO of Applied DNA.
UL, a leading global safety science organization, today announced that together with Applied DNA Sciences Inc. (APDN) they have joined forces to form a strategic partnership that will lay the foundation for a significant new development in product authentication and supply chain traceability. This partnership will enable UL to offer a series of Verification Marks for point-of-origin and product content, utilizing Applied DNA’s SigNature® molecular tags. The DNA tag marks products in order to create a unique “fingerprint” that can be traced throughout a product’s journey in the supply chain.
On a per-share basis, the Stony Brook, New York-based company said it had a loss of 7 cents. The DNA-based security technology company posted revenue of $1 million in the period. In the final minutes of ...
Applied DNA Sciences, Inc. , announced financial results for the fiscal 2018 second quarter ended March 31, 2018.
Applied DNA Sciences, Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), has signed a multi-year license agreement (the “Agreement”) with WestPoint Home, LLC – a premier U.S. textile manufacturing company – to provide CertainT® platform services for their hospitality bedding and textile goods. Under the terms of the Agreement, WestPoint Home has been granted the exclusive right to use Applied DNA’s CertainT platform for its collection of blended duvets, towels, sheets, pillow cases, bed skirts, shams, and decorative pillow products sold for hospitality in Canada, Mexico and the US. Also under the Agreement, WestPoint Home has been granted non-exclusive global CertainT platform rights for various hospitality opportunities.
Applied DNA Sciences, Inc., announces the successful completion of its 1-year consortium research project with BLC Leather Technology Centre Limited who are based in the United Kingdom.
Applied DNA Sciences, Inc. , announced today it plans to release financial results for its fiscal 2018 second quarter ended March 31, 2018 after market close on Thursday, May 3, 2018.
Applied DNA Sciences, Inc. will debut its security print platform solution featuring the Videojet 1860M continuous inkjet printer at INTERPHEX 2018 in Booth 3957 at the Jacob K.
Applied DNA Sciences, Inc., has signed a License and Cooperation Agreement and a related Supply Agreement , effective March 31, 2018, with Colorcon, Inc.